

Patient Name: _ Date of Birth:

Page 1 of 6

Growth Hormono (Arginino / L

CMC84729-001NS Rev. 11/2020 Stimulation Test
BASELINE PATIENT DEMOGRAPHICS
To be completed by the ordering provider.
□ NKDA - No Known Drug Allergies Height: cm Weight: kg Body Surface Area: (m²)
☐ Allergies:
Treatment should begin: ☐ as soon as possible (within a week) ☐ within the month
ORDERS TO BE COMPLETED FOR EACH THERAPY
ADMIT ORDERS
ADMIT ORDERS
✓ Nursing communication patient needs to be fasting for test.
☑ Height and weight
☑ Vital signs
NURSING ORDERS
Please select all appropriate therapy
IV START NURSING ORDERS
☐ Insert peripheral IV
Place PIV if needed or access IVAD if available
☐ lidocaine 1% BUFFERED (J-TIP LIDOCAINE) injection 0.2 mL, inradermal, PRN
when immediate procedure needed
when procedure will take about 1 minute
patient/family preference for procedure
Administration Instructions: NOTE: Do not use this medication in patients with bleeding disorders, platelets ≤ 20,000, or in patients taking anticoagulants, when accessing implanted ports or using a vein that will be utilized for chemotherapy administration, nor for pre-term infants oneonates.
☐ lidocaine - prilocaine (EMLA) cream
Topical, PRN
when more than 60 minutes are available before procedure

☐ Iidocaine - tetracaine (SYNERA) patch

when procedure will take more than 1 hour patient/family preference for procedure

Topical, PRN

when 20 - 30 minutes are available before procedure

when procedure will take more than 1 hour

when anticipated pain is less than 5 mm from skin surface

patient/family preference for procedure

Administration Instructions: NOTE: In children < 3 months of age, or < 5 kg in weight, maximum application time is 1 hour.

	Page 2 of 6



Patient Name: _	
Date of Birth:	

PHYO Growth Hormone (Arginine / L - DOPA)
CMC84729-001NS Rev. 11/2020 Stimulation Test

ORDERS TO BE COMPLETED FOR EACH THERAPY

NURSING ORDERS				
☐ lidocaine with transparent dressing 4 % kit TOPICAL, PRN ☐ when 20 - 30 minutes are available before procedure ☐ when procedure will take more than 1 hour ☐ patient/family preference for procedure				
Select one: ☐ heparin flush 10 - 50 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. This heparin flush should be used with all central lines including IVADs, with the exception of de-accessing the IVAD. ☐ heparin flush 100 - 300 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. For use only when de-accessing IVADs.				
□ Sodium chloride flush 0.9% injection 1 - 20 mL, INTRAVENOUS, PRN, IV line flush □ Sodium chloride - pres free 0.9% injection 1 - 30 mL, INTRAVENOUS, PRN, IV line flush				
PRE - PROCEDURE LABS	INTERVAL	DEFER UNTIL		
☐ Human growth hormone Unit collect	Once			
☐ Cortisol total Unit collect	Once			
☐ T4 Free Unit collect	Once			
☐ Thyroid stimulating hormone Unit collect	Once			
☐ Insulin like growth factor - 1 Unit collect	Once			
☐ Insulin like growth factor - BP - 3 Unit collect	Once			
Luteinizing hormone Unit collect	Once			
☐ Follicle stimulating hormone Unit collect	Once			
☐ Estradiol Unit collect	Once			



Patient Name:	
Date of Birth:	

Page 3 of 6

PHYO Growth Hormone (Arginine / L - DOPA)
CMC84729-001NS Rev. 11/2020 Stimulation Test

ORDERS TO BE COMPLETED FOR EACH THERAPY

	-PROCEDURE LABS, CONTINUED	INTERVAL	DEFER UNTIL	
	Testosterone Unit collect	Once		
	Chromosome karyotype study Unit collect	Once		
	Comprehensive metabolic panel Unit collect	Once		
	Complete blood count with differential Unit collect	Once		
	Tissue transglutaminase IgA Unit collect	Once		
	Immunoglobulin A Unit collect	Once		
	Prolactin Unit collect	Once		
	Adrenocorticotropic hormone (ACTH) Unit collect	Once		
IN	TRA - PROCEDURE			
 ✓ Physician communication order Arginine dose: 0.5 gm / kg, maximum 20 gm. Please enter the dose of arginine in 'gm' to facilitate prior authorization requirements. ✓ arginine 10 % injection INTRAVENOUS, ONCE Give arginine over 30 minutes. Arginine 10 % is a hyperosmolar solution and may be infused with extreme caution via peripheral intravenous access if the patient does not have central venous access. In addition to visualizing, assessing and documenting the PIV site at the beginning and end of the infusion, the PIV site should also be monitored at the following intervals: Every 5 minutes x 3, then every 10 minutes until infusion is complete. Dose:				
	access if the patient does not have central venous acc and end of the infusion, the PIV site should also be mon is complete.	ess. In addition to visualizing,		inning
☑	access if the patient does not have central venous acc and end of the infusion, the PIV site should also be mon is complete.	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (calless than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet)	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (cates than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet) Greater than 30 kg: 500 mg (10 mg / kg to a maximum of carbidopa - levodopa 25 - 250 mg tablet Give at the beginning of arginine infusion.	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (calless than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet) Greater than 30 kg: 500 mg (10 mg / kg to a maximum of carbidopa - levodopa 25 - 250 mg tablet Give at the beginning of arginine infusion. Dose:	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to f 500 mg in adults) (2 tablets)	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (cates than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet) Greater than 30 kg: 500 mg (10 mg / kg to a maximum of carbidopa - levodopa 25 - 250 mg tablet Give at the beginning of arginine infusion. Dose: Therapy appointment request	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to f 500 mg in adults) (2 tablets) intment request:	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (calless than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet) Greater than 30 kg: 500 mg (10 mg / kg to a maximum of carbidopa - levodopa 25 - 250 mg tablet Give at the beginning of arginine infusion. Dose: Therapy appointment request Please select department for the therapy appointment in 365 days. Clinically required scheduled time:	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to f 500 mg in adults) (2 tablets) intment request:	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (calless than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet) Greater than 30 kg: 500 mg (10 mg / kg to a maximum of carbidopa - levodopa 25 - 250 mg tablet Give at the beginning of arginine infusion. Dose: Therapy appointment request Please select department for the therapy appointment is not time test. Patien Dallas Special Procedures Plano Infusion Center	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to f 500 mg in adults) (2 tablets) intment request:	: Every 5 minutes x 3, then every 10 minutes until in	inning
	access if the patient does not have central venous access and end of the infusion, the PIV site should also be mon is complete. Dose: Physician communication order Esoterix recommends using the 25 - 250 mg tablets - (calless than 15 kg: 125 mg (1 / 2 tablet) 15 - 30 kg: 250 mg (1 tablet) Greater than 30 kg: 500 mg (10 mg / kg to a maximum of carbidopa - levodopa 25 - 250 mg tablet Give at the beginning of arginine infusion. Dose: Therapy appointment request Please select department for the therapy appointment is some time test. Patien Dallas Special Procedures	ess. In addition to visualizing, itored at the following intervals arbidopa - L - Dopa) for these to f 500 mg in adults) (2 tablets) intment request:	: Every 5 minutes x 3, then every 10 minutes until in	inning



Patient Name:	
Date of Birth:	

Page 4 of 6

PHYO Growth Hormone (Arginine / L - DOPA) CMC84729-001NS Rev. 11/2020 Stimulation Test

ORDERS TO BE COMPLETED FOR EACH THERAPY

INTRA-PROCEDURE, CONTINUED
☑ Human growth hormone Unit collect draw immediately after arginine infusion complete.
☑ Human growth hormone Unit collect draw 30 minutes after completion of arginine infusion.
☑ Human growth hormone Unit collect draw 60 minutes after completion of arginine infusion.
☐ Human growth hormone Unit collect draw 90 minutes after completion of arginine infusion.
Sodium chloride 0.9 % for fluid bolus infusion 10 mL / kg, INTRAVENOUS, PRN, if blood pressure is < 20 mmHg from baseline, give 10 mL / kg 0.9 % NaCl over 30 minutes. Dose:
ANTIEMETICS
Physician communication order Dosing for ondansetron: < 4 years of age: 0.1 mg / kg 4 - 11 years of age: 4 mg > 12 years of age: 8 mg
☑ Nursing communication
DO NOT give as a pre - medication, may give during or after the test for nausea and administer only one of the ondansetron orders, ODT tablet or IV, do not give both.
☐ ondansetron
ondansetron ODT tablet ORAL, ONCE PRN, nausea / vomiting first line Dose:
ondansetron injection INTRAVENOUS, ONCE, PRN, nausea / vomiting first line when not tolerating oral medications Dose:
EMERGENCY MEDICATIONS

☑ Nursing communication

- 1. Hives or cutaneous reaction only no other system involvement PATIENT IS HAVING A DRUG REACTION:
 - a. Stop the infusion
 - b. Give diphenhydramine as ordered
 - $\textbf{c.} \ \textbf{Check vitals including blood pressure every 5 minutes until further orders from provider.} \\$
 - d. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one
 - e. Notify provider for further orders



Patient Name:	
N-4 6 Di-41-	
Date of Birth:	

Page 5 of 6

PHYO Growth Hormone (Arginine / L - DOPA)
CMC84729-001NS Rev. 11/2020 Stimulation Test

ORDERS TO BE COMPLETED FOR EACH THERAPY

EMERGENCY MEDICATIONS

2. Hives or cutaneous reaction plus one other system, i.e. abdominal cramping, vomiting, hypotension, altered mental status, respiratory distress, mouth / tongue swelling

PATIENT IS HAVING ANAPHYLAXIS:

- a. Stop the infusion
- b. Call code do not wait to give epinephrine
- c. Give epinephrine as ordered
- d. Notify provider

☑ Discontinue line / drain / tube

- e. Check vitals including blood pressure every 5 minutes until the code team arrives.
- f. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one.
- g. Give diphenhydramine once as needed for hives
- h. May repeat epinephrine every 5 minutes x 2 doses for persistent hypotension and respiratory distress with desaturation until code team arrives.
- i. May give albuterol as ordered for wheezing with oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation.

Hypotension is defined as follows:

1 month to 1 year – systolic blood pressure (SBP) less than 70

1 year to 11 years - systolic blood pressure (SBP) less than 70 + (2 x age in years)

11 years to 17 years - systolic blood pressure (SPB) less than 90

OR any age - systolic blood pressure (SPB) drop more than 30% from baseline.

Baseline systolic blood pressure x 0.7 = value below defined as hypotension.

	EPINEPHrine injection (AMPULE / EPI - PEN JR. / EPI - PEN)
	0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L. Dose:
	Cardio / respiratory monitoring rationale for monitoring: high risk patient (please specify risk)
	(Patient receiving infusion with potential infusion reactions); heart rate, respiratory rate, oxygen saturation Rationale for Monitoring: High risk patient (please specify risk) Parameters: heart rate, respiratory rate, oxygen saturation Alarm limits: preset at age specific limits
	diphenhydrAMINE injection
	1 mg / kg, INTRAVENOUS, ONCE PRN,for hives or cutaneous reaction, for 1 dose maximum dose = 50 mg per dose, 300 mg per day. Dose:
	Albuterol for aerosol 0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose Dose:
РО	ST-PROCEDURE

Observe patient for (30 60 90 120) minutes after test and labs are complete, then discontinue PIV and discharge home.



Printed Name of Provider

Patient Name:	
Date of Birth:	

Page 6 of 6

PHYO Growth Hormone (Arginine / L - DOPA) CMC84729-001NS Rev. 11/2020 Stimulation Test

ORDERS TO BE COMPLETED FOR EACH TH	IERAPY		
■ Nursing communication Flush PIV or IVAD with 20 mL 0.9 % sodium chlororocool prior to de - accessing IVAD. Discontinue			D with saline and heparin flush per
□ sodium chloride 0.9% infusion INTRAVENOUS at 0 - 25 mL / hr Dose:			
	(circle one): MD DO		
Signature of Provider	Credentials	Date	Time